IBRX
Immunitybio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.56B
P/E Ratio
—
EPS
$-0.85
Beta
0.07
52W High
$12.43
52W Low
$1.95
50-Day MA
$7.73
200-Day MA
$4.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunitybio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Fundamentals
| Revenue (TTM) | $140.98M |
| Gross Profit (TTM) | $140.04M |
| EBITDA | $-245.41M |
| Operating Margin | -157.90% |
| Return on Equity | 0.00% |
| Return on Assets | -34.40% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $-0.83 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 53.64 |
| EV/Revenue | 56.08 |
| EV/EBITDA | -8.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 167.60% |
| Shares Outstanding | $1.05B |
| Float | $394.04M |
| % Insiders | 62.48% |
| % Institutions | 17.54% |
Historical Volatility
HV 10-Day
49.63%
HV 20-Day
73.96%
HV 30-Day
75.52%
HV 60-Day
98.40%
HV Rank
55.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.25 target)
1
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026